# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target ...
Canaccord Genuity analyst Kyle Mikson maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from ...
BTIG analyst Mark Massaro maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $9 to $6.
Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow ...